Efficacy and Safety of Rheosorbilact® Solution for Infusion, in a Complex Therapy of Pneumonia
Open-label, Randomized, Controlled, With Blind Assessor, Study to Assess Efficacy and Safety of Rheosorbilact®, Solution for Infusion (Yuria-Pharm), in Comparison With Ringer's Lactate,Solution for Infusion, in a Complex Therapy of Pneumonia.
Sponsor: Yuria-Pharm
This PHASE4 trial investigates Pneumonia and is currently completed. Yuria-Pharm leads this study, which shows 8 recorded versions since 2018 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE4
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE4
-
Mar 2020 — Jan 2021 [monthly]
Completed PHASE4
Status: Recruiting → Completed
▶ Show 3 earlier versions
-
Nov 2019 — Mar 2020 [monthly]
Recruiting PHASE4
-
Aug 2019 — Nov 2019 [monthly]
Recruiting PHASE4
-
Feb 2019 — Aug 2019 [monthly]
Recruiting PHASE4
First recorded
Jan 2018
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Yuria-Pharm
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Astana, Kazakhstan , Batumi, Georgia , Chisinau, Moldova , Hanoi, Vietnam , Kutaisi, Georgia , Kyiv, Ukraine , Mykolayiv, Ukraine , Tashkent, Uzbekistan , Tbilisi, Georgia , Thái Bình, Vietnam and 1 more location